Zobrazeno 21 - 30
of 444
pro vyhledávání: ''
Autor:
Kyriakos P. Papadopoulos, Zhengping Wang, R. Donald Harvey, Yang Xu, Alain C. Mita, Ying Ou, Dawn E. Pinchasik, Apostolia Maria Tsimberidou, Lia Gore, Richard E. Cutler
Publikováno v:
British Journal of Clinical Pharmacology. 85:530-539
Aims Oprozomib is an oral, second-generation, irreversible proteasome inhibitor currently in clinical development for haematologic malignancies, including multiple myeloma and other malignancies. Oprozomib is a rare example of a small molecule drug t
Autor:
Xiaoqiang Xiang, Meng-wan Zhang, Wan-jie Niu, Weimin Cai, Size Li, Shasha Jin, Xi-ying Lin, Zheng Jiao
Publikováno v:
British Journal of Clinical Pharmacology
BACKGROUND AND OBJECTIVE: Hypertension is a common comorbidity of patients with COVID-19, SARS or HIV infection. Such patients are often concomitantly treated with antiviral and antihypertensive agents, including ritonavir and nifedipine. Since riton
Publikováno v:
British Journal of Clinical Pharmacology. 84:2477-2482
There is increasing interest in the use of cannabinoids for disease and symptom management, but limited information available regarding their pharmacokinetics and pharmacodynamics to guide prescribers. Cannabis medicines contain a wide variety of che
Autor:
Juan Jose Perez Ruixo, Italo Poggesi, Shirin Bruderer, Lene Nygaard Axelsen, Freya Rasschaert
Publikováno v:
British journal of clinical pharmacology. 87(1)
AIMS Selexipag is a prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension. Cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite, ACT-333679. This study evaluated the inte
Publikováno v:
Br J Clin Pharmacol
AIMS: This study aimed to investigate the potential interaction between Schisandra sphenanthera, imatinib and bosutinib combining in vitro and in silico methods. METHODS: In vitro metabolism of imatinib and bosutinib using recombinant enzymes and hum
Publikováno v:
Br J Clin Pharmacol
Publikováno v:
British Journal of Clinical Pharmacology. 83:2821-2830
AIMS The aims of the present study were to examine the prevalence of high-risk prescribing (HRP) in community-dwelling adults in Ireland from 2011-2015 using consensus-validated indicators, factors associated with HRP, and the variation in HRP betwee
Autor:
Martin Gutierrez, Alexey V. Danilov, Shekman Wong, Lionel D. Lewis, David Chien, Suresh Agarwal, Ahmed Salem, Soham D. Puvvada, Beibei Hu
Publikováno v:
British Journal of Clinical Pharmacology. 83:846-854
Aims To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax. Methods Twelve patients with non-Hodgkin lymphoma (NHL) were enrolled in this Phase 1, open-label
Publikováno v:
British Journal of Clinical Pharmacology
Br J Clin Pharmacol
Br J Clin Pharmacol
Aim We assessed the drug interaction profile of fermented red ginseng with respect to the activity of major cytochrome (CYP) P450 enzymes and of a drug transporter protein, P-glycoprotein (P-gp), in healthy volunteers.\ Methods This study was an open
Autor:
Hamim Zahir, Dolly A. Parasrampuria, Nobuko Matsushima, Kenneth E. Truitt, Jeanne Mendell, Minggao Shi
Publikováno v:
British Journal of Clinical Pharmacology
Aims Edoxaban, a novel factor Xa inhibitor, is a substrate of cytochrome P450 3 A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). Three edoxaban drug–drug interaction studies examined the effects of P-gp inhibitors with varying degrees